Needham lowered the firm's price target on RxSight to $11 from $13 and keeps a Buy rating on the shares after its Q1 results and affirmed revenue guide for 2026. While it is still early days in RXST's re-engagement initiatives, management noted encouraging utilization trends in accounts where they have implemented the commercial strategy, the analyst tells investors in a research note.
